Health Boards
AbbVie have paid $200 million to get Nimble Therapeutics investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis.
Source: nimbletherapeutics.com
Quote:
IL-23 is a cytokine that activates Th17 cells, promoting an inflammatory response that contributes to tissue damage and organ dysfunction.
IL-23R is a receptor involved in the IL-23/IL-17 immune pathway, crucial in the pathogenesis of psoriasis and IBD. Upregulation of IL-23R expression is associated with increased susceptibility to IL-23 signaling, amplifying inflammation and immune responses in psoriasis and inflammatory bowel diseases (IBD), and underpinning the significant clinical efficacy of IL-23 blocking antibodies in these diseases. IL-23R antagonists block the interaction between IL-23 and its receptor, inhibiting the Th17 inflammatory pathway, cytokine production and IL23R upregulation, alleviating inflammation.
We are developing an innovative oral IL-23R antagonist by combining potent activity with gut stability and extended half-life. This medication will offer a more effective oral therapy option for patients seeking less invasive, more effective and convenient treatments.
Source: nimbletherapeutics.com